Abstract
BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.
METHODS: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.
RESULTS: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.
CONCLUSION: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.
| Original language | English |
|---|---|
| Pages (from-to) | 312-314 |
| Number of pages | 3 |
| Journal | Multiple Sclerosis and Related Disorders |
| Volume | 27 |
| DOIs | |
| Publication status | E-pub ahead of print - Nov 13 2018 |
Fingerprint
Cite this
Tocilizumab in MOG-antibody spectrum disorder : a case report. / Novi, G; Gastaldi, M; Franciotta, D; Pesce, G; Benedetti, L; Uccelli, A.
In: Multiple Sclerosis and Related Disorders, Vol. 27, 13.11.2018, p. 312-314.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tocilizumab in MOG-antibody spectrum disorder
T2 - a case report
AU - Novi, G
AU - Gastaldi, M
AU - Franciotta, D
AU - Pesce, G
AU - Benedetti, L
AU - Uccelli, A
N1 - Copyright © 2018. Published by Elsevier B.V.
PY - 2018/11/13
Y1 - 2018/11/13
N2 - BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.METHODS: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.RESULTS: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.CONCLUSION: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.
AB - BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.METHODS: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.RESULTS: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.CONCLUSION: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.
U2 - 10.1016/j.msard.2018.11.012
DO - 10.1016/j.msard.2018.11.012
M3 - Article
C2 - 30469022
VL - 27
SP - 312
EP - 314
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
ER -